Sumitomo Pharma America, Inc.
Clinical trials sponsored by Sumitomo Pharma America, Inc., explained in plain language.
US subsidiary of Japanese pharmaceutical company developing treatments for CNS and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Prostate cancer drug ORGOVYX under Real-World scrutiny
Disease control CompletedThis study follows nearly 1,000 prostate cancer patients taking ORGOVYX (relugolix) to see how the drug works in everyday medical practice. Researchers will track side effects, quality of life, and disease progression. The goal is to understand the drug's real-world safety and ef…
Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Prostate cancer drug showdown: which is safer for the heart?
Disease control CompletedThis completed Phase 3 study compared the risk of major heart problems between two hormone therapies—relugolix (a pill) and leuprolide (an injection)—in 387 men with prostate cancer. The trial was stopped early by the sponsor, but enrolled patients could continue treatment for up…
Phase: PHASE3 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Healthy volunteers needed to test new myelofibrosis drug's absorption
Knowledge-focused CompletedThis study looked at how well two different capsule forms of TP-3654 are absorbed by the body and whether taking them with food changes absorption. It involved 24 healthy adults and was completed. The results will help design future studies for people with myelofibrosis, a bone m…
Phase: PHASE1 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC